Viewing Study NCT01831466

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:42 PM
Ignite Modification Date: 2025-12-28 @ 7:27 AM
Study NCT ID: NCT01831466
Status: COMPLETED
Last Update Posted: 2015-11-25
First Post: 2013-03-28
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Tofacitinib Ointment For Chronic Plaque Psoriasis
Sponsor:
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Raw JSON

{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['France']}, 'conditionBrowseModule': {'meshes': [{'id': 'D011565', 'term': 'Psoriasis'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D008224', 'term': 'Lymphoma, Follicular'}, {'id': 'D011537', 'term': 'Pruritus'}], 'ancestors': [{'id': 'D017444', 'term': 'Skin Diseases, Papulosquamous'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D008228', 'term': 'Lymphoma, Non-Hodgkin'}, {'id': 'D008223', 'term': 'Lymphoma'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D012877', 'term': 'Skin Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrials.gov_Inquiries@pfizer.com', 'phone': '1-800-718-1021', 'title': 'Pfizer ClinicalTrials.gov Call Center', 'organization': 'Pfizer, Inc.'}, 'certainAgreement': {'otherDetails': 'The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The PI must remove any previously undisclosed Confidential Information (other than the Study results themselves) before public release.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}, 'limitationsAndCaveats': {'description': 'Efficacy results for participants in the severe population were not reported since this was considered an exploratory population.'}}, 'adverseEventsModule': {'timeFrame': 'SAEs were assessed from informed consent through and including 28 calendar days after last administration of study treatment. Non-SAEs were recorded from time of first dose of study treatment through last participant visit.', 'description': 'The same event may appear as both an AE and an SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study. All AEs (including treatment area AEs) are presented.', 'eventGroups': [{'id': 'EG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.', 'otherNumAtRisk': 71, 'otherNumAffected': 30, 'seriousNumAtRisk': 71, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.', 'otherNumAtRisk': 70, 'otherNumAffected': 29, 'seriousNumAtRisk': 70, 'seriousNumAffected': 5}, {'id': 'EG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.', 'otherNumAtRisk': 71, 'otherNumAffected': 27, 'seriousNumAtRisk': 71, 'seriousNumAffected': 2}, {'id': 'EG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.', 'otherNumAtRisk': 70, 'otherNumAffected': 34, 'seriousNumAtRisk': 70, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.', 'otherNumAtRisk': 74, 'otherNumAffected': 28, 'seriousNumAtRisk': 74, 'seriousNumAffected': 2}, {'id': 'EG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.', 'otherNumAtRisk': 74, 'otherNumAffected': 40, 'seriousNumAtRisk': 74, 'seriousNumAffected': 1}, {'id': 'EG006', 'title': 'Severe: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.', 'otherNumAtRisk': 7, 'otherNumAffected': 2, 'seriousNumAtRisk': 7, 'seriousNumAffected': 0}, {'id': 'EG007', 'title': 'Severe: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.', 'otherNumAtRisk': 7, 'otherNumAffected': 4, 'seriousNumAtRisk': 7, 'seriousNumAffected': 0}, {'id': 'EG008', 'title': 'Severe: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of severe (4) applied placebo ointment (vehicle), BID for 12 weeks.', 'otherNumAtRisk': 7, 'otherNumAffected': 4, 'seriousNumAtRisk': 7, 'seriousNumAffected': 0}, {'id': 'EG009', 'title': 'Severe: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.', 'otherNumAtRisk': 7, 'otherNumAffected': 3, 'seriousNumAtRisk': 7, 'seriousNumAffected': 0}, {'id': 'EG010', 'title': 'Severe: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.', 'otherNumAtRisk': 6, 'otherNumAffected': 2, 'seriousNumAtRisk': 6, 'seriousNumAffected': 0}, {'id': 'EG011', 'title': 'Severe: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of severe (4) applied placebo ointment (vehicle), QD for 12 weeks.', 'otherNumAtRisk': 7, 'otherNumAffected': 2, 'seriousNumAtRisk': 7, 'seriousNumAffected': 1}], 'otherEvents': [{'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Leukocytosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Leukopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Pancytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Cerumen impaction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Ear discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Vertigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Ear and labyrinth disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Erythema of eyelid', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Eyelid oedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Lacrimation increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Abdominal pain upper', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Chronic gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Dental caries', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Dyspepsia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Food poisoning', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Gastrooesophageal reflux disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Hiatus hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Inguinal hernia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Tongue ulceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Application site pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Application site papules', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Influenza like illness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Oedema peripheral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Seasonal allergy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Immune system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Bacteriuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Chronic tonsillitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Conjunctivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Ear infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Fungal infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Gastroenteritis viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Gastrointestinal viral infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Gingivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Infected bites', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Influenza', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 7}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 11}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Oral candidiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Oral herpes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Otitis externa', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Paronychia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Pharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Pulpitis dental', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Pyelonephritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Rash pustular', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Rhinitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Tooth abscess', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Tooth infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Viral upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Accident at work', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Arthropod bite', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Burns first degree', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Drug dispensing error', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Foot fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Laceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Muscle strain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Post-traumatic neck syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Procedural pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Scar', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Skin abrasion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Blood cholesterol increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Blood creatinine increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Blood triglycerides increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Eosinophil percentage increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Gamma-glutamyltransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 1}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Liver function test abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Low density lipoprotein increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Vitamin B12 decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'White blood cell count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Dehydration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Hypercholesterolaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Hyperglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Hyperlipidaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Hypertriglyceridaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Hypoglycaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Hypokalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Hypomagnesaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Type 2 diabetes mellitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Back pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Exostosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Joint range of motion decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Joint stiffness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Neck pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Pain in extremity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Psoriatic arthropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Spinal osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Squamous cell carcinoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Dysaesthesia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Generalised tonic-clonic seizure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Migraine', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Tension headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Anxiety', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Depression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Stress', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Haematuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Nephrolithiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Proteinuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Erectile dysfunction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Asthma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Catarrh', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Dry throat', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Nasal congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 1}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Oropharyngeal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Paranasal sinus discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Respiratory tract congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Sinus congestion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Sneezing', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Acne', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Dermal cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Dermatitis contact', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Dry skin', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Erythema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Hyperhidrosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Intertrigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Nail psoriasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Onychoclasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Psoriasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 7}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 6}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 6}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 2}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Rash macular', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Skin burning sensation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Skin fissures', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Skin lesion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Vasculitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Hypothyroidism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Endocrine disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Abdominal tenderness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Application site pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Cystitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Cystitis escherichia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Erysipelas', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Impetigo', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Intervertebral disc degeneration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Lipoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Glycosuria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Vaginal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 1}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Reproductive system and breast disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Cough', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}], 'seriousEvents': [{'term': 'Arrhythmia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Atrial fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Cardiac failure congestive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Non-cardiac chest pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Systemic inflammatory response syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Abdominal wound dehiscence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Diabetes mellitus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Osteoarthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Psoriatic arthropathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}, {'term': 'Transient ischaemic attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 70, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 74, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 7, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 6, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 7, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 17.1'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (≥) 2 Grade/Point Improvement From Baseline at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '70', 'groupId': 'OG001'}, {'value': '71', 'groupId': 'OG002'}, {'value': '70', 'groupId': 'OG003'}, {'value': '74', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '21.1', 'groupId': 'OG000'}, {'value': '12.9', 'groupId': 'OG001'}, {'value': '16.9', 'groupId': 'OG002'}, {'value': '20.0', 'groupId': 'OG003'}, {'value': '21.6', 'groupId': 'OG004'}, {'value': '17.6', 'groupId': 'OG005'}]}]}], 'analyses': [{'pValue': '0.5425', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Difference in response rates', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '3.9', 'ciLowerLimit': '-4.3', 'ciUpperLimit': '12.0', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.36', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}, {'pValue': '0.4976', 'groupIds': ['OG001', 'OG002'], 'paramType': 'Difference in response rates', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '-4.0', 'ciLowerLimit': '-11.5', 'ciUpperLimit': '3.5', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.87', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}, {'pValue': '0.6039', 'groupIds': ['OG003', 'OG005'], 'paramType': 'Difference in response rates', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '3.3', 'ciLowerLimit': '-4.9', 'ciUpperLimit': '11.5', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.36', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}, {'pValue': '0.5279', 'groupIds': ['OG004', 'OG005'], 'paramType': 'Difference in response rate', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '4.0', 'ciLowerLimit': '-4.1', 'ciUpperLimit': '12.1', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '6.34', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 12', 'description': 'Clinical signs of plaque psoriasis (erythema \\[E\\], induration \\[I\\], and scaling \\[S\\]) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The mild/moderate full analysis set (FASm) included all participants in the FAS with a baseline PGA-C disease severity of mild (2) or moderate (3). A participant with a missing value was considered a non-responder.'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '70', 'groupId': 'OG001'}, {'value': '71', 'groupId': 'OG002'}, {'value': '70', 'groupId': 'OG003'}, {'value': '74', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '22.5', 'groupId': 'OG000'}, {'value': '10.0', 'groupId': 'OG001'}, {'value': '11.3', 'groupId': 'OG002'}, {'value': '18.6', 'groupId': 'OG003'}, {'value': '14.9', 'groupId': 'OG004'}, {'value': '8.1', 'groupId': 'OG005'}]}]}], 'analyses': [{'pValue': '0.0710', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Difference in response rates', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '10.8', 'ciLowerLimit': '3.1', 'ciUpperLimit': '18.5', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.99', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}, {'pValue': '0.8175', 'groupIds': ['OG001', 'OG002'], 'paramType': 'Difference in response rates', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '-1.2', 'ciLowerLimit': '-7.9', 'ciUpperLimit': '5.5', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.20', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}, {'pValue': '0.0513', 'groupIds': ['OG003', 'OG005'], 'paramType': 'Difference in response rates', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '11.0', 'ciLowerLimit': '3.8', 'ciUpperLimit': '18.2', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.63', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}, {'pValue': '0.2021', 'groupIds': ['OG004', 'OG005'], 'paramType': 'Difference in response rates', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '80', 'paramValue': '6.7', 'ciLowerLimit': '-0.0', 'ciUpperLimit': '13.4', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '5.23', 'statisticalMethod': 'Cochran-Mantel-Haenszel', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 8', 'description': 'Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. A participant with a missing value was considered a non-responder.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '70', 'groupId': 'OG001'}, {'value': '71', 'groupId': 'OG002'}, {'value': '70', 'groupId': 'OG003'}, {'value': '74', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '33.8', 'groupId': 'OG000'}, {'value': '25.7', 'groupId': 'OG001'}, {'value': '23.9', 'groupId': 'OG002'}, {'value': '27.1', 'groupId': 'OG003'}, {'value': '29.7', 'groupId': 'OG004'}, {'value': '23.0', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 12', 'description': 'Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. A participant with a missing value was considered a non-responder.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '70', 'groupId': 'OG001'}, {'value': '71', 'groupId': 'OG002'}, {'value': '70', 'groupId': 'OG003'}, {'value': '74', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '36.6', 'groupId': 'OG000'}, {'value': '20.0', 'groupId': 'OG001'}, {'value': '22.5', 'groupId': 'OG002'}, {'value': '32.9', 'groupId': 'OG003'}, {'value': '21.6', 'groupId': 'OG004'}, {'value': '12.2', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 8', 'description': 'Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. A participant with a missing value was considered a non-responder.'}, {'type': 'SECONDARY', 'title': "Percentage of Participants Achieving a Gestalt Physician's Global Assessment (PGA-G) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12", 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '70', 'groupId': 'OG001'}, {'value': '71', 'groupId': 'OG002'}, {'value': '70', 'groupId': 'OG003'}, {'value': '74', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '18.3', 'groupId': 'OG000'}, {'value': '11.4', 'groupId': 'OG001'}, {'value': '14.1', 'groupId': 'OG002'}, {'value': '15.7', 'groupId': 'OG003'}, {'value': '18.9', 'groupId': 'OG004'}, {'value': '12.2', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 12', 'description': 'Clinical signs of plaque psoriasis (E, I and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. After scoring each of the PGA subscores, a clinical evaluator of psoriasis performed an assessment of the overall severity of psoriasis and assigned a PGA-G score and category. 0=Clear, except for any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation) and 1=almost clear, the psoriasis is not entirely cleared and remaining plaques are light pink (not including post inflammatory hyperpigmentation), and/or have barely palpable elevation and/or have occasional fine scale. The PGA-G was a static assessment; i.e., without regard to a previous assessment.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. A participant with a missing value was considered a non-responder.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving a PGA-G Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '70', 'groupId': 'OG001'}, {'value': '71', 'groupId': 'OG002'}, {'value': '70', 'groupId': 'OG003'}, {'value': '74', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '21.1', 'groupId': 'OG000'}, {'value': '7.1', 'groupId': 'OG001'}, {'value': '11.3', 'groupId': 'OG002'}, {'value': '15.7', 'groupId': 'OG003'}, {'value': '9.5', 'groupId': 'OG004'}, {'value': '4.1', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 8', 'description': 'Clinical signs of plaque psoriasis (E, I and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. After scoring each of the PGA subscores, a clinical evaluator of psoriasis performed an assessment of the overall severity of psoriasis and assigned a PGA-G score and category. 0=Clear, except for any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation) and 1=almost clear, the psoriasis is not entirely cleared and remaining plaques are light pink (not including post inflammatory hyperpigmentation), and/or have barely palpable elevation and/or have occasional fine scale. The PGA-G was a static assessment; i.e., without regard to a previous assessment.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. A participant with a missing value was considered a non-responder.'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline to Week 12 in Psoriasis Area and Severity Index (PASI)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '58', 'groupId': 'OG000'}, {'value': '57', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '62', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '-36.6', 'spread': '40.88', 'groupId': 'OG000'}, {'value': '-35.7', 'spread': '43.78', 'groupId': 'OG001'}, {'value': '-32.0', 'spread': '49.47', 'groupId': 'OG002'}, {'value': '-38.6', 'spread': '36.37', 'groupId': 'OG003'}, {'value': '-31.4', 'spread': '42.36', 'groupId': 'OG004'}, {'value': '-30.0', 'spread': '38.68', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 12', 'description': 'Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent (%) area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\\*area score\\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \\<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.', 'unitOfMeasure': 'Percent Change from Baseline', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. Only observed data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline to Week 8 in PASI', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '60', 'groupId': 'OG003'}, {'value': '67', 'groupId': 'OG004'}, {'value': '58', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '-36.7', 'spread': '36.01', 'groupId': 'OG000'}, {'value': '-29.1', 'spread': '40.86', 'groupId': 'OG001'}, {'value': '-28.8', 'spread': '37.06', 'groupId': 'OG002'}, {'value': '-36.5', 'spread': '33.87', 'groupId': 'OG003'}, {'value': '-29.0', 'spread': '29.47', 'groupId': 'OG004'}, {'value': '-27.1', 'spread': '32.93', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 8', 'description': 'Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\\*area score\\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \\<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.', 'unitOfMeasure': 'Percent Change from Baseline', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. Only observed data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving at Least a 75% Reduction in PASI Response (PASI75), Relative to Baseline at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '70', 'groupId': 'OG001'}, {'value': '71', 'groupId': 'OG002'}, {'value': '70', 'groupId': 'OG003'}, {'value': '74', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '16.9', 'groupId': 'OG000'}, {'value': '12.9', 'groupId': 'OG001'}, {'value': '12.7', 'groupId': 'OG002'}, {'value': '15.7', 'groupId': 'OG003'}, {'value': '10.8', 'groupId': 'OG004'}, {'value': '6.8', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 12', 'description': 'Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\\*area score\\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \\<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. A participant with a missing value was considered a non-responder.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving PASI75, Relative to Baseline at Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '70', 'groupId': 'OG001'}, {'value': '71', 'groupId': 'OG002'}, {'value': '70', 'groupId': 'OG003'}, {'value': '74', 'groupId': 'OG004'}, {'value': '74', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '14.1', 'groupId': 'OG000'}, {'value': '8.6', 'groupId': 'OG001'}, {'value': '7.0', 'groupId': 'OG002'}, {'value': '15.7', 'groupId': 'OG003'}, {'value': '6.8', 'groupId': 'OG004'}, {'value': '6.8', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 8', 'description': 'Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\\*area score\\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \\<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. A participant with a missing value was considered a non-responder.'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline to Week 12 in Body Surface Area (BSA) Affected With Psoriasis', 'denoms': [{'units': 'Participants', 'counts': [{'value': '58', 'groupId': 'OG000'}, {'value': '57', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '62', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '-32.8', 'spread': '40.92', 'groupId': 'OG000'}, {'value': '-27.5', 'spread': '36.40', 'groupId': 'OG001'}, {'value': '-27.7', 'spread': '43.43', 'groupId': 'OG002'}, {'value': '-24.6', 'spread': '36.29', 'groupId': 'OG003'}, {'value': '-15.6', 'spread': '36.63', 'groupId': 'OG004'}, {'value': '-11.2', 'spread': '56.38', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 12', 'description': 'Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. BSA (%)=the sum of the BSAs of the 4 body regions. BSA assessment excluded head and neck, palms, finger nails, soles and toe nails.', 'unitOfMeasure': 'Percent Change from Baseline', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. Only observed data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline to Week 8 in BSA Affected With Psoriasis', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '60', 'groupId': 'OG003'}, {'value': '67', 'groupId': 'OG004'}, {'value': '58', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '-25.4', 'spread': '44.75', 'groupId': 'OG000'}, {'value': '-22.5', 'spread': '35.87', 'groupId': 'OG001'}, {'value': '-20.5', 'spread': '34.90', 'groupId': 'OG002'}, {'value': '-17.8', 'spread': '28.59', 'groupId': 'OG003'}, {'value': '-9.0', 'spread': '30.08', 'groupId': 'OG004'}, {'value': '-11.7', 'spread': '38.29', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 8', 'description': 'Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. BSA (%)=the sum of the BSAs of the 4 body regions. BSA assessment excluded head and neck, palms, finger nails, soles and toe nails.', 'unitOfMeasure': 'Percent Change from Baseline', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. Only observed data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Week 12 in Clinic-Based Itch Severity Item (ISI) Scores', 'denoms': [{'units': 'Participants', 'counts': [{'value': '57', 'groupId': 'OG000'}, {'value': '57', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '52', 'groupId': 'OG003'}, {'value': '62', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '-2.88', 'spread': '3.140', 'groupId': 'OG000'}, {'value': '-2.89', 'spread': '3.320', 'groupId': 'OG001'}, {'value': '-1.73', 'spread': '2.460', 'groupId': 'OG002'}, {'value': '-2.38', 'spread': '3.182', 'groupId': 'OG003'}, {'value': '-1.94', 'spread': '3.151', 'groupId': 'OG004'}, {'value': '-1.50', 'spread': '2.961', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 12', 'description': 'The severity of itch (pruritus) due to psoriasis was assessed using the ISI. Participants were asked to assess their "worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "no itching" (0) and "worst possible itching" (10) at the ends. Participants completed the ISI assessments at the clinic (i.e., clinic-based).', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. Only observed data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Week 8 in Clinic-Based ISI Scores', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '59', 'groupId': 'OG003'}, {'value': '66', 'groupId': 'OG004'}, {'value': '58', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '-3.07', 'spread': '2.971', 'groupId': 'OG000'}, {'value': '-2.38', 'spread': '2.984', 'groupId': 'OG001'}, {'value': '-1.45', 'spread': '2.847', 'groupId': 'OG002'}, {'value': '-2.49', 'spread': '2.769', 'groupId': 'OG003'}, {'value': '-1.91', 'spread': '3.166', 'groupId': 'OG004'}, {'value': '-1.34', 'spread': '3.285', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 8', 'description': 'The severity of itch (pruritus) due to psoriasis was assessed using the ISI. Participants were asked to assess their "worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "no itching" (0) and "worst possible itching" (10) at the ends. Participants completed the ISI assessments at the clinic (i.e., clinic-based).', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. Only observed data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Week 12 in the Dermatology Life Quality Index (DLQI) Total Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '58', 'groupId': 'OG000'}, {'value': '57', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '62', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '-4.6', 'spread': '5.55', 'groupId': 'OG000'}, {'value': '-3.2', 'spread': '5.32', 'groupId': 'OG001'}, {'value': '-2.6', 'spread': '5.45', 'groupId': 'OG002'}, {'value': '-5.6', 'spread': '7.04', 'groupId': 'OG003'}, {'value': '-3.3', 'spread': '5.97', 'groupId': 'OG004'}, {'value': '-2.3', 'spread': '6.34', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 12', 'description': 'DLQI is the dermatology-specific quality of life measure used for psoriatic population. The 10-item questionnaire assesses participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. Only observed data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline to Week 8 in the DLQI Total Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '60', 'groupId': 'OG003'}, {'value': '67', 'groupId': 'OG004'}, {'value': '58', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '-4.6', 'spread': '5.16', 'groupId': 'OG000'}, {'value': '-2.6', 'spread': '4.98', 'groupId': 'OG001'}, {'value': '-2.8', 'spread': '4.01', 'groupId': 'OG002'}, {'value': '-5.0', 'spread': '5.85', 'groupId': 'OG003'}, {'value': '-2.7', 'spread': '4.79', 'groupId': 'OG004'}, {'value': '-2.2', 'spread': '5.63', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline, Week 8', 'description': 'DLQI is the dermatology-specific quality of life measure used for psoriatic population. The 10-item questionnaire assesses participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.', 'unitOfMeasure': 'Score on a Scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. Only observed data were analyzed.'}, {'type': 'SECONDARY', 'title': "Percentage of Participants Achieving a Patient's Global Assessment (PtGA) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12 for Participants With a PtGA Score ≥2 at Baseline", 'denoms': [{'units': 'Participants', 'counts': [{'value': '57', 'groupId': 'OG000'}, {'value': '57', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '62', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '8.8', 'groupId': 'OG000'}, {'value': '17.5', 'groupId': 'OG001'}, {'value': '7.3', 'groupId': 'OG002'}, {'value': '13.2', 'groupId': 'OG003'}, {'value': '14.5', 'groupId': 'OG004'}, {'value': '7.7', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 12', 'description': 'The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. Only observed data were analyzed.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving a PtGA Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8 for Participants With a PtGA Score ≥2 at Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '60', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}, {'value': '55', 'groupId': 'OG002'}, {'value': '60', 'groupId': 'OG003'}, {'value': '67', 'groupId': 'OG004'}, {'value': '58', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'OG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'OG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'OG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'OG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'OG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.0', 'groupId': 'OG000'}, {'value': '6.3', 'groupId': 'OG001'}, {'value': '10.9', 'groupId': 'OG002'}, {'value': '10.0', 'groupId': 'OG003'}, {'value': '6.0', 'groupId': 'OG004'}, {'value': '1.7', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Week 8', 'description': 'The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).', 'unitOfMeasure': 'Percentage of Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'FASm. Only observed data were analyzed.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/Gram (mg/g) Twice Daily (BID)', 'description': "Participants with a baseline Calculated Physician's Global Assessment (PGA-C) score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks."}, {'id': 'FG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'FG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'FG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g Once Daily (QD)', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'FG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'FG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}, {'id': 'FG006', 'title': 'Severe: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'FG007', 'title': 'Severe: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'FG008', 'title': 'Severe: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of severe (4) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'FG009', 'title': 'Severe: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'FG010', 'title': 'Severe: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'FG011', 'title': 'Severe: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of severe (4) applied placebo ointment (vehicle), QD for 12 weeks.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'comment': 'Treated', 'groupId': 'FG000', 'numSubjects': '71'}, {'comment': 'Treated', 'groupId': 'FG001', 'numSubjects': '70'}, {'comment': 'Treated', 'groupId': 'FG002', 'numSubjects': '71'}, {'comment': 'Treated', 'groupId': 'FG003', 'numSubjects': '70'}, {'comment': 'Treated', 'groupId': 'FG004', 'numSubjects': '74'}, {'comment': 'Treated', 'groupId': 'FG005', 'numSubjects': '74'}, {'comment': 'Treated', 'groupId': 'FG006', 'numSubjects': '7'}, {'comment': 'Treated', 'groupId': 'FG007', 'numSubjects': '7'}, {'comment': 'Treated', 'groupId': 'FG008', 'numSubjects': '7'}, {'comment': 'Treated', 'groupId': 'FG009', 'numSubjects': '7'}, {'comment': 'Treated', 'groupId': 'FG010', 'numSubjects': '6'}, {'comment': 'Treated', 'groupId': 'FG011', 'numSubjects': '7'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '55'}, {'groupId': 'FG001', 'numSubjects': '52'}, {'groupId': 'FG002', 'numSubjects': '48'}, {'groupId': 'FG003', 'numSubjects': '51'}, {'groupId': 'FG004', 'numSubjects': '57'}, {'groupId': 'FG005', 'numSubjects': '48'}, {'groupId': 'FG006', 'numSubjects': '6'}, {'groupId': 'FG007', 'numSubjects': '5'}, {'groupId': 'FG008', 'numSubjects': '4'}, {'groupId': 'FG009', 'numSubjects': '2'}, {'groupId': 'FG010', 'numSubjects': '4'}, {'groupId': 'FG011', 'numSubjects': '3'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '16'}, {'groupId': 'FG001', 'numSubjects': '18'}, {'groupId': 'FG002', 'numSubjects': '23'}, {'groupId': 'FG003', 'numSubjects': '19'}, {'groupId': 'FG004', 'numSubjects': '17'}, {'groupId': 'FG005', 'numSubjects': '26'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '2'}, {'groupId': 'FG008', 'numSubjects': '3'}, {'groupId': 'FG009', 'numSubjects': '5'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '4'}]}], 'dropWithdraws': [{'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}]}, {'type': 'Non-compliance with study treatment', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '0'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '3'}, {'groupId': 'FG003', 'numSubjects': '3'}, {'groupId': 'FG004', 'numSubjects': '3'}, {'groupId': 'FG005', 'numSubjects': '5'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '1'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '3'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '0'}, {'groupId': 'FG008', 'numSubjects': '0'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '1'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '8'}, {'groupId': 'FG002', 'numSubjects': '7'}, {'groupId': 'FG003', 'numSubjects': '6'}, {'groupId': 'FG004', 'numSubjects': '9'}, {'groupId': 'FG005', 'numSubjects': '8'}, {'groupId': 'FG006', 'numSubjects': '1'}, {'groupId': 'FG007', 'numSubjects': '1'}, {'groupId': 'FG008', 'numSubjects': '2'}, {'groupId': 'FG009', 'numSubjects': '2'}, {'groupId': 'FG010', 'numSubjects': '2'}, {'groupId': 'FG011', 'numSubjects': '0'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '6'}, {'groupId': 'FG004', 'numSubjects': '3'}, {'groupId': 'FG005', 'numSubjects': '7'}, {'groupId': 'FG006', 'numSubjects': '0'}, {'groupId': 'FG007', 'numSubjects': '1'}, {'groupId': 'FG008', 'numSubjects': '1'}, {'groupId': 'FG009', 'numSubjects': '1'}, {'groupId': 'FG010', 'numSubjects': '0'}, {'groupId': 'FG011', 'numSubjects': '2'}]}]}], 'recruitmentDetails': 'Participants with mild (PGA-C score of 2), moderate (PGA-C score of 3), or severe (PGA-C score of 4) chronic plaque psoriasis were recruited for this study. The primary analysis population for this study included only the participants with mild and moderate disease.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'BG000'}, {'value': '70', 'groupId': 'BG001'}, {'value': '71', 'groupId': 'BG002'}, {'value': '70', 'groupId': 'BG003'}, {'value': '74', 'groupId': 'BG004'}, {'value': '74', 'groupId': 'BG005'}, {'value': '7', 'groupId': 'BG006'}, {'value': '7', 'groupId': 'BG007'}, {'value': '7', 'groupId': 'BG008'}, {'value': '7', 'groupId': 'BG009'}, {'value': '6', 'groupId': 'BG010'}, {'value': '7', 'groupId': 'BG011'}, {'value': '471', 'groupId': 'BG012'}]}], 'groups': [{'id': 'BG000', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'BG001', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'BG002', 'title': 'Mild/Moderate: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'BG003', 'title': 'Mild/Moderate: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'BG004', 'title': 'Mild/Moderate: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'BG005', 'title': 'Mild/Moderate: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.'}, {'id': 'BG006', 'title': 'Severe: Tofacitinib 20 mg/g BID', 'description': 'Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.'}, {'id': 'BG007', 'title': 'Severe: Tofacitinib 10 mg/g BID', 'description': 'Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.'}, {'id': 'BG008', 'title': 'Severe: Placebo (Vehicle) BID', 'description': 'Participants with a baseline PGA-C score of severe (4) applied placebo ointment (vehicle), BID for 12 weeks.'}, {'id': 'BG009', 'title': 'Severe: Tofacitinib 20 mg/g QD', 'description': 'Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.'}, {'id': 'BG010', 'title': 'Severe: Tofacitinib 10 mg/g QD', 'description': 'Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.'}, {'id': 'BG011', 'title': 'Severe: Placebo (Vehicle) QD', 'description': 'Participants with a baseline PGA-C score of severe (4) applied placebo ointment (vehicle), QD for 12 weeks.'}, {'id': 'BG012', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Customized', 'classes': [{'title': '< 18 years', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '0', 'groupId': 'BG008'}, {'value': '0', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '0', 'groupId': 'BG012'}]}]}, {'title': '18-44 years', 'categories': [{'measurements': [{'value': '30', 'groupId': 'BG000'}, {'value': '23', 'groupId': 'BG001'}, {'value': '25', 'groupId': 'BG002'}, {'value': '21', 'groupId': 'BG003'}, {'value': '30', 'groupId': 'BG004'}, {'value': '25', 'groupId': 'BG005'}, {'value': '2', 'groupId': 'BG006'}, {'value': '0', 'groupId': 'BG007'}, {'value': '1', 'groupId': 'BG008'}, {'value': '3', 'groupId': 'BG009'}, {'value': '3', 'groupId': 'BG010'}, {'value': '2', 'groupId': 'BG011'}, {'value': '165', 'groupId': 'BG012'}]}]}, {'title': '45-64 years', 'categories': [{'measurements': [{'value': '28', 'groupId': 'BG000'}, {'value': '34', 'groupId': 'BG001'}, {'value': '34', 'groupId': 'BG002'}, {'value': '38', 'groupId': 'BG003'}, {'value': '35', 'groupId': 'BG004'}, {'value': '39', 'groupId': 'BG005'}, {'value': '4', 'groupId': 'BG006'}, {'value': '6', 'groupId': 'BG007'}, {'value': '4', 'groupId': 'BG008'}, {'value': '2', 'groupId': 'BG009'}, {'value': '2', 'groupId': 'BG010'}, {'value': '2', 'groupId': 'BG011'}, {'value': '228', 'groupId': 'BG012'}]}]}, {'title': '>= 65 years', 'categories': [{'measurements': [{'value': '13', 'groupId': 'BG000'}, {'value': '13', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}, {'value': '11', 'groupId': 'BG003'}, {'value': '9', 'groupId': 'BG004'}, {'value': '10', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}, {'value': '1', 'groupId': 'BG007'}, {'value': '2', 'groupId': 'BG008'}, {'value': '2', 'groupId': 'BG009'}, {'value': '1', 'groupId': 'BG010'}, {'value': '3', 'groupId': 'BG011'}, {'value': '78', 'groupId': 'BG012'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '28', 'groupId': 'BG000'}, {'value': '23', 'groupId': 'BG001'}, {'value': '30', 'groupId': 'BG002'}, {'value': '33', 'groupId': 'BG003'}, {'value': '24', 'groupId': 'BG004'}, {'value': '32', 'groupId': 'BG005'}, {'value': '1', 'groupId': 'BG006'}, {'value': '3', 'groupId': 'BG007'}, {'value': '1', 'groupId': 'BG008'}, {'value': '1', 'groupId': 'BG009'}, {'value': '0', 'groupId': 'BG010'}, {'value': '0', 'groupId': 'BG011'}, {'value': '176', 'groupId': 'BG012'}]}, {'title': 'Male', 'measurements': [{'value': '43', 'groupId': 'BG000'}, {'value': '47', 'groupId': 'BG001'}, {'value': '41', 'groupId': 'BG002'}, {'value': '37', 'groupId': 'BG003'}, {'value': '50', 'groupId': 'BG004'}, {'value': '42', 'groupId': 'BG005'}, {'value': '6', 'groupId': 'BG006'}, {'value': '4', 'groupId': 'BG007'}, {'value': '6', 'groupId': 'BG008'}, {'value': '6', 'groupId': 'BG009'}, {'value': '6', 'groupId': 'BG010'}, {'value': '7', 'groupId': 'BG011'}, {'value': '295', 'groupId': 'BG012'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Full Analysis Set (FAS) - included all participants who were randomized to the study, received at least one dose of the randomized investigational drug (tofacitinib or vehicle), and were in a baseline PGA-C category of mild (2), moderate (3) or severe (4).'}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 476}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2013-05'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2015-10', 'completionDateStruct': {'date': '2014-09', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2015-10-26', 'studyFirstSubmitDate': '2013-03-28', 'resultsFirstSubmitDate': '2015-09-15', 'studyFirstSubmitQcDate': '2013-04-10', 'lastUpdatePostDateStruct': {'date': '2015-11-25', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2015-10-26', 'studyFirstPostDateStruct': {'date': '2013-04-15', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2015-11-25', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2014-09', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (≥) 2 Grade/Point Improvement From Baseline at Week 12', 'timeFrame': 'Baseline, Week 12', 'description': 'Clinical signs of plaque psoriasis (erythema \\[E\\], induration \\[I\\], and scaling \\[S\\]) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.'}, {'measure': 'Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8', 'timeFrame': 'Baseline, Week 8', 'description': 'Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.'}], 'secondaryOutcomes': [{'measure': 'Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 12', 'timeFrame': 'Week 12', 'description': 'Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.'}, {'measure': 'Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 8', 'timeFrame': 'Week 8', 'description': 'Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.'}, {'measure': "Percentage of Participants Achieving a Gestalt Physician's Global Assessment (PGA-G) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12", 'timeFrame': 'Baseline, Week 12', 'description': 'Clinical signs of plaque psoriasis (E, I and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. After scoring each of the PGA subscores, a clinical evaluator of psoriasis performed an assessment of the overall severity of psoriasis and assigned a PGA-G score and category. 0=Clear, except for any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation) and 1=almost clear, the psoriasis is not entirely cleared and remaining plaques are light pink (not including post inflammatory hyperpigmentation), and/or have barely palpable elevation and/or have occasional fine scale. The PGA-G was a static assessment; i.e., without regard to a previous assessment.'}, {'measure': 'Percentage of Participants Achieving a PGA-G Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8', 'timeFrame': 'Baseline, Week 8', 'description': 'Clinical signs of plaque psoriasis (E, I and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. After scoring each of the PGA subscores, a clinical evaluator of psoriasis performed an assessment of the overall severity of psoriasis and assigned a PGA-G score and category. 0=Clear, except for any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation) and 1=almost clear, the psoriasis is not entirely cleared and remaining plaques are light pink (not including post inflammatory hyperpigmentation), and/or have barely palpable elevation and/or have occasional fine scale. The PGA-G was a static assessment; i.e., without regard to a previous assessment.'}, {'measure': 'Percent Change From Baseline to Week 12 in Psoriasis Area and Severity Index (PASI)', 'timeFrame': 'Baseline, Week 12', 'description': 'Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent (%) area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\\*area score\\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \\<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.'}, {'measure': 'Percent Change From Baseline to Week 8 in PASI', 'timeFrame': 'Baseline, Week 8', 'description': 'Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\\*area score\\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \\<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.'}, {'measure': 'Percentage of Participants Achieving at Least a 75% Reduction in PASI Response (PASI75), Relative to Baseline at Week 12', 'timeFrame': 'Baseline, Week 12', 'description': 'Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\\*area score\\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \\<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.'}, {'measure': 'Percentage of Participants Achieving PASI75, Relative to Baseline at Week 8', 'timeFrame': 'Baseline, Week 8', 'description': 'Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\\*area score\\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \\<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.'}, {'measure': 'Percent Change From Baseline to Week 12 in Body Surface Area (BSA) Affected With Psoriasis', 'timeFrame': 'Baseline, Week 12', 'description': 'Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. BSA (%)=the sum of the BSAs of the 4 body regions. BSA assessment excluded head and neck, palms, finger nails, soles and toe nails.'}, {'measure': 'Percent Change From Baseline to Week 8 in BSA Affected With Psoriasis', 'timeFrame': 'Baseline, Week 8', 'description': 'Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. BSA (%)=the sum of the BSAs of the 4 body regions. BSA assessment excluded head and neck, palms, finger nails, soles and toe nails.'}, {'measure': 'Change From Baseline to Week 12 in Clinic-Based Itch Severity Item (ISI) Scores', 'timeFrame': 'Baseline, Week 12', 'description': 'The severity of itch (pruritus) due to psoriasis was assessed using the ISI. Participants were asked to assess their "worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "no itching" (0) and "worst possible itching" (10) at the ends. Participants completed the ISI assessments at the clinic (i.e., clinic-based).'}, {'measure': 'Change From Baseline to Week 8 in Clinic-Based ISI Scores', 'timeFrame': 'Baseline, Week 8', 'description': 'The severity of itch (pruritus) due to psoriasis was assessed using the ISI. Participants were asked to assess their "worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "no itching" (0) and "worst possible itching" (10) at the ends. Participants completed the ISI assessments at the clinic (i.e., clinic-based).'}, {'measure': 'Change From Baseline to Week 12 in the Dermatology Life Quality Index (DLQI) Total Score', 'timeFrame': 'Baseline, Week 12', 'description': 'DLQI is the dermatology-specific quality of life measure used for psoriatic population. The 10-item questionnaire assesses participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.'}, {'measure': 'Change From Baseline to Week 8 in the DLQI Total Score', 'timeFrame': 'Baseline, Week 8', 'description': 'DLQI is the dermatology-specific quality of life measure used for psoriatic population. The 10-item questionnaire assesses participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.'}, {'measure': "Percentage of Participants Achieving a Patient's Global Assessment (PtGA) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12 for Participants With a PtGA Score ≥2 at Baseline", 'timeFrame': 'Baseline, Week 12', 'description': 'The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).'}, {'measure': 'Percentage of Participants Achieving a PtGA Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8 for Participants With a PtGA Score ≥2 at Baseline', 'timeFrame': 'Baseline, Week 8', 'description': 'The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['plaque psoriasis', 'vulgaris', 'topical treatment', 'skin diseases', 'papulosquamous', 'Tofacitinib', 'CP-690550', 'Xeljanz', 'psoriasis', 'moderate', 'severe', 'itch', 'nail psoriasis'], 'conditions': ['Psoriasis Vulgaris', 'Psoriasis']}, 'referencesModule': {'references': [{'pmid': '27716172', 'type': 'DERIVED', 'citation': 'Papp KA, Bissonnette R, Gooderham M, Feldman SR, Iversen L, Soung J, Draelos Z, Mamolo C, Purohit V, Wang C, Ports WC. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. BMC Dermatol. 2016 Oct 3;16(1):15. doi: 10.1186/s12895-016-0051-4.'}], 'seeAlsoLinks': [{'url': 'https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921082&StudyName=Tofacitinib%20Ointment%20For%20Chronic%20Plaque%20Psoriasis', 'label': 'To obtain contact information for a study center near you, click here.'}]}, 'descriptionModule': {'briefSummary': 'The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested. The safety and effectiveness of tofacitinib ointment used for 12 weeks will be compared to the safety and effectiveness of placebo ointment (vehicle) used for 12 weeks.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Have mild, moderate or severe plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Baseline\n* At Baseline, have plaque psoriasis covering 2% to 20% of total body surface area (BSA) on the trunk and limbs (excluding palms, soles, and nails)\n* If received certain treatments, should be off treatment for a minimum period of time (washout)\n\nExclusion Criteria:\n\n* Currently have non-plaque forms of psoriasis or drug-induced psoriasis\n* Require treatment with or cannot stop medication(s) prohibited during the study\n* Have certain laboratory abnormalities at Baseline\n* Current or history of certain infections\n* Females who are pregnant, breastfeeding, or are of childbearing potential not using highly effective contraception'}, 'identificationModule': {'nctId': 'NCT01831466', 'briefTitle': 'Tofacitinib Ointment For Chronic Plaque Psoriasis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Pfizer'}, 'officialTitle': 'A Phase 2b, Multi-site, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study Of The Efficacy, Safety, Local Tolerability And Pharmacokinetics Of 2 Dose Strengths And 2 Regimens Of Tofacitinib Ointment In Subjects With Chronic Plaque Psoriasis.', 'orgStudyIdInfo': {'id': 'A3921082'}, 'secondaryIdInfos': [{'id': '2012-005645-20', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Treatment Group A', 'interventionNames': ['Drug: tofacitinib ointment 20 mg/g']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment Group B', 'interventionNames': ['Drug: tofacitinib ointment 10 mg/g']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Treatment Group C', 'interventionNames': ['Drug: placebo ointment (vehicle)']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment Group D', 'interventionNames': ['Drug: tofacitinib ointment 20 mg/g']}, {'type': 'EXPERIMENTAL', 'label': 'Treatment Group E', 'interventionNames': ['Drug: tofacitinib ointment 10 mg/g']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Treatment Group F', 'interventionNames': ['Drug: placebo ointment (vehicle)']}], 'interventions': [{'name': 'tofacitinib ointment 20 mg/g', 'type': 'DRUG', 'description': 'tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks', 'armGroupLabels': ['Treatment Group A']}, {'name': 'tofacitinib ointment 10 mg/g', 'type': 'DRUG', 'description': 'tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks', 'armGroupLabels': ['Treatment Group B']}, {'name': 'placebo ointment (vehicle)', 'type': 'DRUG', 'description': 'placebo ointment (vehicle) BID (twice daily) for 12 weeks', 'armGroupLabels': ['Treatment Group C']}, {'name': 'tofacitinib ointment 20 mg/g', 'type': 'DRUG', 'description': 'tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks', 'armGroupLabels': ['Treatment Group D']}, {'name': 'tofacitinib ointment 10 mg/g', 'type': 'DRUG', 'description': 'tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks', 'armGroupLabels': ['Treatment Group E']}, {'name': 'placebo ointment (vehicle)', 'type': 'DRUG', 'description': 'placebo ointment (vehicle) QD (once daily) for 12 weeks', 'armGroupLabels': ['Treatment Group F']}]}, 'contactsLocationsModule': {'locations': [{'zip': '71913', 'city': 'Hot Springs', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Burke Pharmaceutical Research', 'geoPoint': {'lat': 34.5037, 'lon': -93.05518}}, {'zip': '93304', 'city': 'Bakersfield', 'state': 'California', 'country': 'United States', 'facility': 'Bakersfield Dermatology and Skin Cancer Medical Center', 'geoPoint': {'lat': 35.37329, 'lon': -119.01871}}, {'zip': '92697', 'city': 'Irvine', 'state': 'California', 'country': 'United States', 'facility': 'UC Irvine Dermatology Research', 'geoPoint': {'lat': 33.66946, 'lon': -117.82311}}, {'zip': '90045', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Dermatology Research Associates', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '32073', 'city': 'Orange Park', 'state': 'Florida', 'country': 'United States', 'facility': 'Park Avenue Dermatology, PA', 'geoPoint': {'lat': 30.16607, 'lon': -81.70648}}, {'zip': '33609', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'Olympian Clinical Research', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '30022', 'city': 'Alpharetta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Atlanta Dermatology, Vein & Research Center', 'geoPoint': {'lat': 34.07538, 'lon': -84.29409}}, {'zip': '30342', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Advanced Medical Research, Inc', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '30263', 'city': 'Newnan', 'state': 'Georgia', 'country': 'United States', 'facility': 'MedaPhase Inc.', 'geoPoint': {'lat': 33.38067, 'lon': -84.79966}}, {'zip': '60118', 'city': 'West Dundee', 'state': 'Illinois', 'country': 'United States', 'facility': 'Dundee Dermatology', 'geoPoint': {'lat': 42.09808, 'lon': -88.28286}}, {'zip': '02111', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Tufts Medical Center', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '02114', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Massachusetts General Hospital - Clinical Unit for Research Trials in Skin (CURTIS)', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '48038', 'city': 'Clinton Township', 'state': 'Michigan', 'country': 'United States', 'facility': 'Michigan Center for Skin Care Research', 'geoPoint': {'lat': 42.58698, 'lon': -82.91992}}, {'zip': '27262', 'city': 'High Point', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Dermatology Consulting Services', 'geoPoint': {'lat': 35.95569, 'lon': -80.00532}}, {'zip': '27104', 'city': 'Winston-Salem', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Wake Forest University Health Sciences', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}}, {'zip': '45249', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'Radiant Research, Inc.', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '97210', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Oregon Dermatology and Research Center', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '97223', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Oregon Medical Research Center, PC', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '02919', 'city': 'Johnston', 'state': 'Rhode Island', 'country': 'United States', 'facility': 'Clinical Partners, LLC', 'geoPoint': {'lat': 41.82186, 'lon': -71.50675}}, {'zip': '02903', 'city': 'Providence', 'state': 'Rhode Island', 'country': 'United States', 'facility': 'Rhode Island Hospital', 'geoPoint': {'lat': 41.82399, 'lon': -71.41283}}, {'zip': '29650', 'city': 'Greer', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Radiant Research, Inc.', 'geoPoint': {'lat': 34.93873, 'lon': -82.22706}}, {'zip': '57702', 'city': 'Rapid City', 'state': 'South Dakota', 'country': 'United States', 'facility': 'Health Concepts', 'geoPoint': {'lat': 44.08054, 'lon': -103.23101}}, {'zip': '37203', 'city': 'Nashville', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Dermatology Research Associates', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '76011', 'city': 'Arlington', 'state': 'Texas', 'country': 'United States', 'facility': 'Arlington Research Center Inc.', 'geoPoint': {'lat': 32.73569, 'lon': -97.10807}}, {'zip': '75230', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Dermatology Treatment and Research Center', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '75246', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Menter Dermatology Research Institute', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '77056', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Suzanne Bruce and Associates, PA', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Lee Medical Associates', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Progressive Clinical Research', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': 'T5K 1X3', 'city': 'Edmonton', 'state': 'Alberta', 'country': 'Canada', 'facility': 'Stratica Medical', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'zip': 'R3C 1R4', 'city': 'Winnipeg', 'state': 'Manitoba', 'country': 'Canada', 'facility': 'Dermadvances Research', 'geoPoint': {'lat': 49.8844, 'lon': -97.14704}}, {'zip': 'L1S 7K8', 'city': 'Ajax', 'state': 'Ontario', 'country': 'Canada', 'facility': 'CCA Medical Research Corporation', 'geoPoint': {'lat': 43.85012, 'lon': -79.03288}}, {'zip': 'L4M 6L2', 'city': 'Barrie', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Ultranova Skincare', 'geoPoint': {'lat': 44.40011, 'lon': -79.66634}}, {'zip': 'L8N 1V6', 'city': 'Hamilton', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Dermatrials Research', 'geoPoint': {'lat': 43.25011, 'lon': -79.84963}}, {'zip': 'N6A 3H7', 'city': 'London', 'state': 'Ontario', 'country': 'Canada', 'facility': 'The Guenther Dermatology Research Centre', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'zip': 'L3P1X2', 'city': 'Markham', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Lynderm Research Inc', 'geoPoint': {'lat': 43.86682, 'lon': -79.2663}}, {'zip': 'K9J 1Z2', 'city': 'Peterborough', 'state': 'Ontario', 'country': 'Canada', 'facility': 'SKiN Centre for Dermatology', 'geoPoint': {'lat': 44.30012, 'lon': -78.31623}}, {'zip': 'N2J 1C4', 'city': 'Waterloo', 'state': 'Ontario', 'country': 'Canada', 'facility': 'K. Papp Clinical Research Inc.', 'geoPoint': {'lat': 43.4668, 'lon': -80.51639}}, {'zip': 'N8W 1E6', 'city': 'Windsor', 'state': 'Ontario', 'country': 'Canada', 'facility': 'XLR8 Medical Research', 'geoPoint': {'lat': 42.30008, 'lon': -83.01654}}, {'zip': 'H2K 4L5', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Innovaderm Research Inc', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': 'H3Z 2S6', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Siena Medical Research', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': '8000', 'city': 'Aarhus C', 'country': 'Denmark', 'facility': 'Dermatologisk Afdeling S', 'geoPoint': {'lat': 56.16558, 'lon': 10.21231}}, {'zip': '7400', 'city': 'Herning', 'country': 'Denmark', 'facility': 'Hudklinikken Herning', 'geoPoint': {'lat': 56.13615, 'lon': 8.97662}}, {'zip': '60-539', 'city': 'Poznan', 'state': 'Greater Poland Voivodeship', 'country': 'Poland', 'facility': 'NZOZ Solumed', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'zip': '02-758', 'city': 'Warsaw', 'state': 'Masovian Voivodeship', 'country': 'Poland', 'facility': 'Klinika Ambroziak ESTEDERM Sp. z o.o.SKA', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '15-351', 'city': 'Bialystok', 'country': 'Poland', 'facility': 'Zdrowie Osteo-Medic s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'zip': '15-879', 'city': 'Bialystok', 'country': 'Poland', 'facility': 'NZOZ Centrum Osteoporozy i Chorob Kostno-Stawowych J. Badurski Spolka Jawna', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'zip': '80-152', 'city': 'Gdansk', 'country': 'Poland', 'facility': 'Pomorskie Centrum Traumatologii im.Mikolaja Kopernika w Gdansku Oddzial Dermatologii', 'geoPoint': {'lat': 54.35227, 'lon': 18.64912}}, {'zip': '31-501', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Krakowskie Centrum Medyczne Sp. z o.o.', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '20-080', 'city': 'Lublin', 'country': 'Poland', 'facility': 'Maxxmed Centrum Zdrowia i Urody', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'zip': '61-841', 'city': 'Poznan', 'country': 'Poland', 'facility': 'Gabinet Lekarski RTG USG Dr n. med. Pawel Skrzywanek; Pracownia Radiologiczna', 'geoPoint': {'lat': 52.40692, 'lon': 16.92993}}, {'zip': '01-817', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'High-Med. Przychodnia Specjalistyczna', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '04-141', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Wojskowy Instytut Medyczny', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '51-318', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'NZOZ multiMedica', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}], 'overallOfficials': [{'name': 'Pfizer CT.gov Call Center', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Pfizer'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pfizer', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}